OOIR: Observatory of International Research

Papers

(The TQCC of Molecular Neurodegeneration is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
LRRK2 kinase activity regulates Parkinson’s disease-relevant lipids at the lysosome	630
Molecular hallmarks of excitatory and inhibitory neuronal resilience to Alzheimer’s disease	354
Altered trafficking of Kv1-Kvβ2 leads to neuronal hyperexcitability and memory deficits in amyloid-β pathology	268
Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer’s disease through disrupted regulated intramembrane proteolysis	257
Synaptic control of retinal ganglion cell survival and axon regeneration	240
Retraction Note: Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5– implications for dementia with lewy bodies	188
Obesity-driven phosphatidylethanolamine dysregulation impairs neuroimmune crosstalk and accelerates Alzheimer’s pathogenesis	185
TREM2 dependent and independent functions of microglia in Alzheimer’s disease	168
Regulation of the hippocampal translatome by Apoer2-ICD release	161
Mis-localization of endogenous TDP-43 leads to ALS-like early-stage metabolic dysfunction and progressive motor deficits	158
Tau interactome and RNA binding proteins in neurodegenerative diseases	143
Emerging targets of α-synuclein spreading in α-synucleinopathies: a review of mechanistic pathways and interventions	139
Organelle stress in NLRP3 inflammasome: a central mediator of neurodegenerative diseases	133
Death-associated protein kinase 1-dependent SENP1 degradation increases tau SUMOylation and leads to cognitive dysfunction in a mouse model for tauopathy	125
The Parkinson’s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons	112
Cautions on utilizing plasma GFAP level as a biomarker for reactive astrocytes in neurodegenerative diseases	110
A genome-wide search for pleiotropy in more than 100,000 harmonized longitudinal cognitive domain scores	108
Inhibition of soluble epoxide hydrolase confers neuroprotection and restores microglial homeostasis in a tauopathy mouse model	107
Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	106
Astrocytic autophagy plasticity modulates Aβ clearance and cognitive function in Alzheimer’s disease	104
Cerebrospinal fluid markers link to synaptic plasticity responses and Alzheimer’s disease genetic pathways	104
Microglia sensing of peripheral signals that bridge the brain and body	103
Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	97
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap	93
Multi-omics insights into GBA1-associated Parkinson’s disease: interplay of genomics, transcriptomics, proteomics, and lipidomics	93

The role of NURR1 in metabolic abnormalities of Parkinson’s disease	86
Recombinant cathepsins B and L promote α-synuclein clearance and restore lysosomal function in human and murine models with α-synuclein pathology	85
Immunotherapy against tau fragment diminishes AD pathology, improving synaptic function and cognition	78
HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	78
Single-cell peripheral immunoprofiling of Lewy body and Parkinson’s disease in a multi-site cohort	76
Human VCP mutant ALS/FTD microglia display immune and lysosomal phenotypes independently of GPNMB	74
Unravelling cell type-specific responses to Parkinson’s Disease at single cell resolution	73
Multi-region brain transcriptomic analysis of amyotrophic lateral sclerosis reveals widespread RNA alterations and substantial cerebellum involvement	73
In Memoriam of Edward H. Koo, MD 1954–2025	71
Correction: Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	70
Impaired nucleocytoplasmic transport in SOD1-mediated ALS	69
Combination therapy using GDNF and cell transplant in Parkinson’s disease	68
Repetitive transcranial magnetic stimulation alleviates motor impairment in Parkinson’s disease: association with peripheral inflammatory regulatory T-cells and SYT6	67
Pharmacological restoration of impaired autophagy in retinal ganglion cells prevents abnormal mitochondrial accumulation and glaucomatous neurodegeneration	66
Finding memo: versatile interactions of the VPS10p-Domain receptors in Alzheimer’s disease	65
BAX activation in mouse retinal ganglion cells occurs in two temporally and mechanistically distinct steps	64
Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer’s disease	63
Clinical progression and genetic pathways in body-first and brain-first Parkinson’s disease	62
α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease	61
APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants	61
Entering the era of precision medicine to treat amyotrophic lateral sclerosis	61
Plasma platelet-derived growth factor receptor-β decrease correlates with blood-brain barrier damage in Alzheimer’s disease	60
Correction: The major TMEM106B dementia risk allele affects TMEM106B protein levels, fibril formation, and myelin lipid homeostasis in the ageing human hippocampus	60
Deficits in mitochondrial TCA cycle and OXPHOS precede rod photoreceptor degeneration during chronic HIF activation	59
A perspective on Alzheimer’s disease: exploring the potential of terminal/paradoxical lucidity and psychedelics	59
ASO-mediated knock-down of GPNMB in mutant-GRN and in Grn-deficient peripheral myeloid cells disrupts lysosomal function and immune responses	58
TMEM106B aggregation in neurodegenerative diseases: linking genetics to function	57
Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes	56
Using mass spectrometry to validate mouse models of tauopathy	56
Evidence suggesting that microglia make amyloid from neuronally expressed APP: a hypothesis	55
The transcription factor combination MEF2 and KLF7 promotes axonal sprouting in the injured spinal cord with functional improvement and regeneration-associated gene expression	55
RETRACTED ARTICLE: Aging exacerbates the brain inflammatory micro-environment contributing to α-synuclein pathology and functional deficits in a mouse model of DLB/PD	53
The PKCι-β-arrestin2 axis disrupts SORLA retrograde trafficking, driving its degradation and amyloid pathology in Alzheimer’s disease	53
Common features of neurodegenerative disease: exploring the brain-eye connection and beyond (part 2): the 2021 pre-symposium of the 15th international conference on Alzheimer’s and Parkinson’s disease	53
Correction: HDGFL2 cryptic proteins report presence of TDP-43 pathology in neurodegenerative diseases	52
The endotoxin hypothesis of Alzheimer’s disease	52
Dementia with lewy bodies patients with high tau levels display unique proteome profiles	52
Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease	51
Contribution of amyloid deposition from oligodendrocytes in a mouse model of Alzheimer’s disease	51
The role of n-3-derived specialised pro-resolving mediators (SPMs) in microglial mitochondrial respiration and inflammation resolution in Alzheimer’s disease	50
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease	50
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration	50
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia	49
Glial phagocytosis for synapse and toxic proteins in neurodegenerative diseases	49
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM2	48
Diagnostic biomarkers for α-synucleinopathies- state of the art and future developments: a systematic review	48
Cerebrospinal fluid proteome profiling across the Alzheimer’s disease continuum: a step towards solving the equation for ‘X’	46
The Hippo signaling pathway as a therapeutic target in Alzheimer’s disease	46
Correction: Predominant expression of Alzheimer’s disease-associated BIN1 in mature oligodendrocytes and localization to white matter tracts	46
Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer’s disease	46

APOE genotype influences on the brain metabolome of aging mice – role for mitochondrial energetics in mechanisms of resilience in APOE2 genotype	46
Sodium oligomannate alters gut microbiota, reduces cerebral amyloidosis and reactive microglia in a sex-specific manner	45
Sex specific molecular networks and key drivers of Alzheimer’s disease	44
Correction: Network proteomics of the Lewy body dementia brain reveals presynaptic signatures distinct from Alzheimer’s disease	44
Peripheral and central neuroimmune mechanisms in Alzheimer’s disease pathogenesis	44
Correction: Blood–brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism	43
GBA1 inactivation in oligodendrocytes affects myelination and induces neurodegenerative hallmarks and lipid dyshomeostasis in mice	43
Mechanisms of astrocyte aging in reactivity and disease	43
Mitochondria transfer in neurological disorders: the key role of neuroglia	43
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes	42
Amyloid-β (Aβ) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer’s disease	41
NF-κB is a critical mediator of post-mitotic senescence in oligodendrocytes and subsequent white matter loss	41
Correction: Border-associated macrophages promote cerebral amyloid angiopathy and cognitive impairment through vascular oxidative stress	40
Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP	40
Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency	40
Modulation of O-GlcNAc cycling influences α-synuclein amplification, degradation, and associated neuroinflammatory pathology	39
Current strategies in the management of dementia with lewy bodies and future directions based on disease pathophysiology	39
Therapeutic potential of APP antisense oligonucleotides for Alzheimer’s disease and down syndrome-related Alzheimer’s disease	39
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology	38
The molecular fidelity of Aβ pathology in 5xFAD and AppNL−FPsen1P117L mice revealed by cryo-EM	38
Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson’s and other related neurodegenerat	37
Proteomic analysis of APOEε4 carriers implicates lipid metabolism, complement and lymphocyte signaling in cognitive resilience	37
Proteomic landscape of Alzheimer’s disease: emerging technologies, advances and insights (2021 – 2025)	37
Correction: Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis	37
Increased expression of mesencephalic astrocyte-derived neurotrophic factor (MANF) contributes to synapse loss in Alzheimer’s disease	36
BACE1 regulates expression of Clusterin in astrocytes for enhancing clearance of β-amyloid peptides	35
TDP-43 seeding activity in the olfactory mucosa of patients with amyotrophic lateral sclerosis	35
Correction: Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model	35
Age-dependent progression from clearance to vulnerability in the early response of periventricular microglia to α-synuclein toxic species	35
Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies	35
Resistant and Resilient mutations in protection against familial Alzheimer’s disease: learning from nature	35